

VRS-I News Bulletin

Vol. I 2020



Vitreo-Retinal Society - India

VRS-I News Bulletin

Vol. I 2020

VRSI

Governing Council



Dr. Shobhit Chawla
President



Dr. N.S Muralidhar
Vice President



Dr. Raja Narayanan
Honorary Secretary



Dr. Anand Rajendran
Convenor Scientific Committee



Dr. Manisha Agarwal
Jt. Secretary



Dr. Hemanth Murthy
Treasurer



Dr. Prashant Bawankule
Joint Treasurer



Dr. Pukhraj Rishi
Member, Executive Committee



Dr. Manoj Khatri
Member, Executive Committee



Dr. Chaitra Jayadev
Member, Executive Committee



Dr. A Giridhar
Ex-Officio

Newsletter Editor
Dr Raja Narayanan

Sub Editor
Dr Manoj Khatri

Sub Editor
Dr Madanagopalan V G

VRS-I News Bulletin

Vol. I 2020



VRSI 2020
NAGPUR
REGISTRATIONS
OPEN

www.vrsi.in



VRSI-2019 Awards won at Lucknow Awards to be given at Nagpur 2020

Recipient	Session
Dr. Rajani Battu	JM Pahwa
Dr Vivek Dave	Best Poster
Dr. Ekta Rishi	Best Video

VRS-I News Bulletin



Vol. I 2020

28th Annual Meeting at Lucknow



VRS-I News Bulletin



Vol. I 2020

Diabetic Retinopathy CME on 26 January 2020,
Karnal, Haryana.





VRSI Webinar

 **VITREO RETINAL SOCIETY - INDIA**

**1ST VRSI NATIONAL WEBINAR ON
ADVANCED
RETINAL IMAGING**

AN INTERACTIVE UPDATE ON CUTTING EDGE DEVELOPMENTS IN RETINAL IMAGING

APRIL 25, SATURDAY / 5 PM - 7PM

SUPPORTED BY INTAS

[CLICK HERE TO REGISTER](#)

MODERATORS


Dr. Anand Rajendran


Dr. Raja Narayanan

PANELISTS


Dr. Shobhit Chawla


Dr. Giridhar


Dr. Muna Bhende


Dr. Jay Chhablani

-  **OCT Angiography - Basics, Nuances & Pitfalls**
Dr. Unnikrishnan Nair
-  **OCTA in AMD & PCV**
Dr. Daraius Shroff
-  **OCTA in DR and Vascular Occlusions**
Dr. Muna Bhende
-  **OCTA in Inflammatory Pathologies**
Dr. Aniruddha Agarwal
-  **Novel OCT Terms and Biomarkers**
Dr. Pukhraj Rishi
-  **Multicolour Imaging in Macular Diseases**
Dr. Anand Rajendran
-  **Choroidal Imaging and Indices**
Dr. Jay Chhablani
-  **Ultrawide Imaging in Retinal Practice**
Dr. Vinod Aggarwal

 Find us on **facebook**

 Subscribe to our **YouTube Channel**

Dr. Anand Rajendran
Convener - Scientific Committee
Vitreo-Retinal Society of India
Email : convener.scientificcom.vrsi@gmail.com / anandjrjn@gmail.com

 **VITREO RETINAL SOCIETY - INDIA**

**2nd VRSI National Webinar
Retina Practice Guidelines
in the COVID 19 Era**

30th April 2020, 5.00 - 7.00 PM

PANELISTS


Dr. Shobhit Chawla


Dr. Cyrus M Shroff


Dr. Giridhar


Dr. Vishali Gupta


Dr. Prashant Bawankule

MODERATORS


Dr. Anand Rajendran


Dr. Manisha Agarwal

 **Elective Vs emergency surgeries in today's time**
Dr. Atul Kumar

 **Reinventing workflow in the Retina OPD**
Dr. Mahesh P Shanmugam

 **Modifications in protocols for intravitreal injections & lasers**
Dr. Raja Narayanan

 **Pre-op evaluation of a patient**
Dr. N S Muralidhar

 **Working in the OR**
Dr. H.S Trehan

 **Balancing cost to being cautious**
Dr. Dinesh Talwar

Each talk for 10 min and 10 min discussion after each talk

Got any queries pertaining COVID-19 and Retina Practice?
Please write to convener.scientificcom.vrsi@gmail.com or simply reply to this mail with your query.

[CLICK HERE TO WATCH PREVIOUS WEBCAST](#)

 Find us on **facebook**

Subscribe to our **YouTube Channel**

Dr. Anand Rajendran
Convener - Scientific Committee
Vitreo-Retinal Society of India
Email : convener.scientificcom.vrsi@gmail.com / anandjrjn@gmail.com



VRSI Telehealth



Join us for the comprehensive programme on
Telemedicine and Medicolegal

TELEHEALTH 2020

LOGIN AT
WWW.TELEHEALTH2020.ORG

An Online Telemedicine and Medicolegal Education
Programme for Doctors Curated by Country's Top Most
Medicolegal Experts





VRSI Telehealth

Programme Highlight

What to expect:

- Telemedicine in Today's Era
- Understanding Telemedicine Guideline 2020
 - Types and Applications of Telemedicine
 - The Indian Judicial System
 - Legal Aspects of Medicine
- List of Various Acts Applicable to Medical Practitioners
- Negligence and its Types
 - Vicarious Liability
- Understanding Various Forums Related to Medicolegal

... and many more

Enroll today!

Register Now on
<https://forms.gle/9MVG7dYYisGLfj4a8>



PP-OTH-IN-0005-1 dated 04 May 2020



TELEHEALTH 2020

A Telemedicine and Medicolegal
Education programme for
Doctors Designed by Country's
top most medico legal experts

[CLICK HERE TO REGISTER](#)

LIMITED SPOTS. ONLY FIRST 400 ENTRIES.



Dr. Shobhit Chawla



Dr. Raja Narayanan



Dr. Anand Rajendran



Dr. Prashant Bawankule



Dr. Manoj Khatri



Upcoming Events

 **NOVARTIS** | Reimagining Medicine



ONE WORLD FIGHT TOGETHER

-China-India Forum

Date: 15th May 2020 | Time: 13:30 – 14:30

- 13:30-13:35** **China opening**
Derek Chang
BU Head, Novartis China
- 13:35-13:40** **India opening**
Chanakya Misra
BU Head, Novartis India
- 13:40-14:10** **China Practice Sharing:
Ophthalmology Department Management
During COVID-19 Pandemic in China**
Prof. Youxin Chen
Peking Union Medical College, Beijing
- 14:10-14:30** **Q & A**
All


Live Broadcast Link: <http://live.vhall.com/508282440>

OR

Zoom Link: <https://www.zoomus.cn/j/15569326989>

Meeting number: 1532841864

Your privacy is important to us.

To know more about our privacy policy please click here: 
link - <https://www.novartis.com/sites/www.novartis.com/files/novartis-general-privacy-notice-for-business-partners.pdf>



Upcoming Events



LIVE STREAM

Optimal management of nAMD A review of the evidence



Dr Dilsher Dhoot



Dr Charles Wykoff



Dr Rishi Singh



Dr Peter Kaiser

Please join Bayer Ophthalmology for this educational webinar – streamed live to you, at home!

Four world-renowned physicians from the US will present the latest updates on the management of nAMD and share their personal insights during a live Q&A session.

Thursday, 28 May 2020 - 5:00 - 6:30 pm (IST)

Agenda:

- Introduction – **Dr Alex Hunyor**
- Comparing the molecular properties of available anti-VEGF therapies – **Dr Peter Kaiser**
- Achieving optimal vision gains and interval extension – **Dr Charles Wykoff**
- The role of retinal fluid in the management of nAMD – **Dr Rishi Singh**
- Additional considerations for anti-VEGF therapy: Insights from clinical trials and real world experience – **Dr Dilsher Dhoot**
- Live Q&A – **Dr Dilsher Dhoot**

Meeting close

Link for Registration

<https://conferenceshare.com.au/app/streamgate/viewer/watch/presentation/5ea6c4fe632fc67ae49b7672>

PP-EYL-IN-0077-1 Last Modified on May 2020



Bayer Zydus Pharma

For further information please contact:
Bayer Zydus Pharma Private Limited,
Bayer House, central Avenue, Hiranandani Estate, Thane -400607,
Maharashtra India. E-mail : medicalinfo.india@bayerzyduspharma.com

Disclaimer:- For the use of intended recipient, medical practitioner or healthcare professionals only.



Membership Directory Update

VRS-I is in the process of updating its database with the latest address, email id and contact number of the member. This exercise shall help in improving better communication with the members.

As a member, you can verify or update your profile using any one of the following ways.

OPTION 1



1. Login to www.vrsi.in using your email id and password.
2. Visit "My Profile".
3. Verify the data and make necessary changes.
4. Save.

The secretariat shall update the records into the database within 2 working days and acknowledge

OPTION 2



Send your VRSI membership number, full name, address, email id and mobile number to support@vrsi.in. Your information shall be changed and acknowledged in 2 working days.


OPTION 3



Whatsapp VRSI membership number, full name, address, email id and mobile number to 9843846776 and be assured of a revert after the update within 2 days.



Don't know your VRSI membership number? Needn't worry. Send us an email and hear from us within 2 working days.



Your friend, a VRSI member?

Please share the details of your 'VRSI member' friend with us by email or whatsapp. We shall contact them, verify the data and update the profile.



VRS-I CME

VRS-I invites members of non-metro cities to submit proposals for CME & Diabetic Retinopathy programs. VRS-I will provide limited support and help promote the screening of Diabetic Retinopathy. Interested members can submit their proposal with Objective, Target audience, and Budget to Dr. Raja Narayanan, secretaryvrsi@gmail.com

Call for submissions to

The Official Newsletter of the Vitreo Retinal Society of India

Original articles:

These include randomized controlled trials, intervention studies, studies of screening and diagnostic test, outcome studies, cost effectiveness analyses, case-control series, and surveys with high response rate. The text of original articles amounting to up to 3000 words (excluding Abstract, references and Tables) should be divided into sections with the headings Abstract, Key-words, Introduction, Material and Methods, Results, Discussion, References, Tables and Figure legends.

Review Articles:

It is expected that these articles would be written by individuals who have done substantial work on the subject or are considered experts in the field. A short summary of the work done by the contributor(s) in the field of review should accompany the manuscript.

The prescribed word count is up to 3000 words excluding tables, references and abstract. The manuscript may have about 90 references. The manuscript should have an unstructured Abstract (250 words) representing an accurate summary of the article. The section titles would depend upon the topic reviewed. Authors submitting review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.

Case reports / Challenging case / Innovations / Instruments / Techniques

New, interesting, challenging, rare cases, innovations, instruments and techniques can be reported. They should be unique and providing learning point for the readers. Manuscripts with clinical significance or implications will be given priority. These communications could be of up to 1000 words (excluding Abstract and references) and should have the following headings: Abstract (unstructured), Key-words, Introduction, Case, Discussion, Reference, Tables and Legends in that order.

The manuscript could be of up to 1000 words (excluding references and abstract) and could be supported with up to 10 references. Case Reports could be authored by up to four authors.

Guidelines for the manuscript submission in VRSI Newsletter: www.vrsi.co.in

Please submit manuscripts to Dr Anand Rajendran: anandrjn@gmail.com